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Abstract
Multiple myeloma (MM) is the third most common hematologic malignancy in Korea. 
Historically, the incidence of MM in Korea has been lower than that in Western pop-
ulations, although there is growing evidence that the incidence of MM in Asian pop-
ulations, including Korea, is increasing rapidly. Despite advances in the management of 
MM, patients will ultimately relapse or become refractory to their current treatment, and 
alternative therapeutic options are required in the relapsed/refractory setting. In Korea, 
although lenalidomide/dexamethasone is indicated for the treatment of relapsed or re-
fractory MM (RRMM) in patients who have received at least one prior therapy, lenalido-
mide is reimbursable specifically only in patients with RRMM who have failed bortezo-
mib-based treatment. Based on evidence from pivotal multinational clinical trials as well 
as recent studies in Asia, including Korea, lenalidomide/dexamethasone is an effective 
treatment option for patients with RRMM, regardless of age or disease status. Adverse 
events associated with lenalidomide/dexamethasone, including hematologic toxicity, ve-
nous thromboembolism, fatigue, rash, infection, and muscle cramps, are largely predict-
able and preventable/manageable with appropriate patient monitoring and/or the use of 
standard supportive medication and dose adjustment/interruption. Lenalidomide/dex-
amethasone provides an optimal response when used at first relapse, and treatment 
should be continued long term until disease progression. With appropriate modification 
of the lenalidomide starting dose, lenalidomide/dexamethasone is effective in patients 
with renal impairment and/or cytopenia. This review presents updated evidence from the 
published clinical literature and provides recommendations from an expert panel of 
Korean physicians regarding the use of lenalidomide/dexamethasone in patients with 
RRMM.
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INTRODUCTION
Multiple myeloma (MM), a plasma cell neoplasm, accounts 
for approximately 10% of all hematologic malignancies [1-3]. 
In Western populations, the annual incidence of MM is 
estimated to be about 3–5/100,000 patients [1]. Historically, 
Asian populations have exhibited a lower incidence of MM 
(0.5–3/100,000 patients) [4]. However, there is growing evi-
dence that the incidence of MM in Asian populations is 
increasing rapidly [5], with the incidence of MM in Korea 
doubling between 2000 and 2010 [4]. A recent study from 
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Table 1. Factors for consideration before selecting the appropriate treatment for patients with relapsed or refractory multiple myeloma.
Factor Characteristic
Regimen-related • Level of evidence (single vs. combo, novel vs. cytotoxic)
• Previous induction or salvage regimens
• Toxicity of regimen 
• Mode of administration
• Availability of novel drugs or drug combinations
• Access to clinical trials of new drugs 
Disease-related • Duration of response to initial therapy
• FISH or cytogenetic profiles [e.g., t(4;14) or del(17p)]
Patient-related • Pre-existing toxicities (e.g., cumulative myelosuppression, peripheral neuropathy)
• Remission duration achieved previously
• Tolerability profile to prior treatment
• Eligibility for transplantation
• Co-morbid conditions (e.g., renal failure, diabetes mellitus)
• Age
• Performance status
Abbreviation: FISH, fluorescence in situ hybridization.
the Asian Myeloma Network reported that the median age 
of MM patients in Asia (N=3,405) was 62 years, and there 
was a higher prevalence in men than in women [5].
Irrespective of sex, MM currently ranks as the third most 
common hematologic malignancy in Korea, after non- 
Hodgkin’s lymphoma and acute myeloid leukemia (AML) 
[2]. In fact, the incidence of MM has surpassed that of acute 
lymphoblastic leukemia and is approaching the incidence 
of AML [2]. Overall, the incidence of hematologic malig-
nancies, including MM, in Korea is similar to that reported 
in China and Japan [2].
The clinical features and survival outcomes of 3,209 pa-
tients with MM in Korea were reported in an analysis of 
web-based data from the Korean Myeloma Registry [6]. The 
study demonstrated associations between survival outcomes 
and treatment modalities, as well as between outcomes and 
baseline disease characteristics. More recently, epidemiologic 
data from 3,405 symptomatic MM patients in 7 Asian coun-
tries have shown that there are no unique clinical character-
istics of MM that are specific to Asian patients compared 
with Western patients with MM [5].
Although there have been advances in the management 
of MM, allowing patients to achieve improvements in com-
plete response rates and sustained response durations, MM 
patients will nonetheless ultimately relapse or become re-
fractory to their current treatment [3, 7-9]. Alternative ther-
apeutic options are subsequently required in the relapsed 
or refractory setting.
The Korean Ministry of Food and Drug Safety (MFDS) 
approved the use of lenalidomide, a thalidomide derivative, 
in combination with dexamethasone in 2009 for the treat-
ment of patients with relapsed or refractory MM (RRMM) 
who have received at least 1 prior therapy [10].
Lenalidomide has anti-angiogenic, anti-inflammatory, an-
ti-proliferative, and immunomodulatory effects [11]. 
Although the precise cellular targets and molecular processes 
responsible for the actions of immunomodulatory drugs, in-
cluding lenalidomide, in MM have not been elucidated fully, 
a recent landmark study identified cereblon (CRBN: cerebral 
protein with Lon protease) as a primary target of thalidomide 
teratogenicity [12]. Subsequently, the anti-myeloma activity 
of both thalidomide and lenalidomide has been shown to 
be dependent on the presence of CRBN [13, 14].
The combination of lenalidomide and dexamethasone has 
demonstrated efficacy and safety in patients with RRMM 
in 2 large, well-designed pivotal clinical trials conducted, 
respectively, in North America (MM-009) [15] and Europe, 
Israel, and Australia (MM-010) [16]. Compared with place-
bo/dexamethasone, lenalidomide/dexamethasone resulted in 
significant improvements in overall response rate (ORR), 
time-to-progression (TTP), and overall survival (OS). The 
most common adverse events included hematologic toxicity 
and venous thromboembolism (VTE).
Several recent clinical studies conducted in Korea [17], 
China (MM-021) [18], and Japan [19] have also demonstrated 
the efficacy and safety of lenalidomide/dexamethasone in 
Asian patients with RRMM. However, despite the availability 
of clinical practice guidelines for the use of lenalidomide 
in the treatment of RRMM in Caucasian populations [20-24], 
currently, no treatment guidelines have been tailored for 
the Korean population. 
The objective of this article is to present an updated review 
of the current literature on the use of lenalidomide in patients 
with RRMM and to provide specific expert recommendations 
from the Korean perspective. These guidelines are based 
on published literature and the clinical experience of an 
expert panel of Korean clinicians.
INDICATION AND TIMING
A number of factors relating to disease and patient charac-
teristics, as well as treatment regimen, must be considered 
when selecting an appropriate treatment for patients with 
RRMM (Table 1). For example, the duration of response 
can affect outcomes; patients with a duration of remission 
bloodresearch.or.kr Blood Res 2015;50:7-18.
Lenalidomide in relapsed/refractory MM 9
Table 2. Summary of key clinical data from 2 large (＞100 patients) multicenter, noncomparative studies (Korea and China) in Asian patients 
receiving lenalidomide/dexamethasone for relapsed or refractory multiple myeloma [17, 18].
Study 
[reference]
N 
(male/
female)
Median age 
(range) 
[years]
Prior exposure 
to THD and/or 
BOR, N (%)
Overall response 
rate (≥PR), 
N (%)
Median TTP or 
PFS (months) 
[95% CI]
Median OS 
(months)
Adverse events 
(≥ Grade 3, >10% 
incidence)
Korea [17] 110 
(59/51)
62 (37–79) THD: 68 (78.2)
BOR: 103 (93.2)
48 (43.7) TTP: 8.0 [6.3-9.7] 23 Neutropenia (59.1%)
Anemia (43.7%)
Thrombocytopenia (43.6%)
China 
(MM-021)
[18]
187a) 
(116/71)
60 (35–81) THD: 130 (69.5)
BOR: 118 (63.1) 
THD + BOR: 
84 (44.9)  
89 (47.6) PFS: 8.3 [6.5-9.8] NR Anemia (26.1%)
Neutropenia (25.1%)
Thrombocytopenia (14.6%)
Pneumonia (13.1%)
a)Primary efficacy population (safety population: N=199).
Abbreviations: BOR, bortezomib; CI, confidence interval; NR, not reported; OS, overall survival; PFS, progression-free survival; PR, partial 
response; THD, thalidomide; TTP, time to progression.
＜6 months have an inferior response duration compared 
with patients who have a remission duration ＞12 months 
[25]. In addition, different management strategies may be 
needed for patients with rapid disease progression or ag-
gressive relapse compared with patients exhibiting indolent, 
slowly progressive disease relapse [25].
In Korea, lenalidomide, in combination with dex-
amethasone, is indicated (under a special risk management 
program) for the treatment of MM in patients who have 
undergone at least 1 prior therapy [10]. However, there 
is currently a gap between the approved lenalidomide in-
dication and reimbursement guidelines, with lenalidomide 
being reimbursed specifically only in patients with MM who 
have failed bortezomib-based treatment.
The rationale for the indication of lenalidomide/dex-
amethasone in the treatment of RRMM is based on data 
from 2 pivotal clinical studies, MM-009 and MM-010 [15, 
16]. In both studies, the median OS was significantly longer 
with lenalidomide/dexamethasone than with dexamethasone 
alone (29.6 months or not reached vs. 20.2–20.6 months, 
respectively; P＜0.001). ORRs (60–61% vs. 20–24%, re-
spectively; P＜0.001) and the median TTP (11.1–11.3 months 
vs. 4.7 months, respectively; P＜0.001) were also improved 
significantly with lenalidomide/dexamethasone compared 
with dexamethasone alone [15, 16]. Long-term follow-up 
(median 48 months) from the 2 studies demonstrated that 
the benefit of lenalidomide/dexamethasone compared with 
dexamethasone alone remained significant [26]. Similar re-
sponse rates and survival benefits have been reported in 
recently published clinical studies conducted in Korea [17] 
and China (MM-021) [18], each including more than 100 
RRMM patients treated with lenalidomide/dexamethasone 
(Table 2).
Hematologic toxicities (particularly neutropenia) and 
thromboembolic events are the most clinically important 
adverse events associated with lenalidomide/dexamethasone 
treatment [27]. Prevention (see ‘Prophylactic management 
of adverse events’) and treatment (see ‘Treatment of adverse 
events’) strategies for adverse events are discussed in detail 
in this review.
A subgroup analysis of the 2 pivotal clinical trials men-
tioned above revealed that lenalidomide/dexamethasone is 
both effective and tolerable for second-line MM therapy, 
with data indicating that the greatest benefit occurs with 
earlier use of the combination [28]. Patients who had under-
gone 1 prior therapy had significantly prolonged median 
TTP (17.1 months vs. 10.6 months; P=0.026) and pro-
gression-free survival (PFS; 14.1 months vs. 9.5 months, 
P=0.047) compared with patients who had previously re-
ceived more than 1 prior therapy. ORRs were also sig-
nificantly higher in patients experiencing their first relapse 
(66.9% vs. 56.8%, P=0.06), as was the complete plus very 
good partial response rate (39.8% vs. 27.7%, P=0.025). 
Importantly, OS was significantly prolonged for patients 
treated with lenalidomide/dexamethasone who had only re-
ceived 1 prior therapy, compared with patients treated in 
later salvage lines (median of 42.0 months vs. 35.8 months, 
P=0.041) and, despite longer treatment, there were no differ-
ences in toxicity, dose reductions, or discontinuations [28]. 
Similar outcomes were also reported in study MM-021 con-
ducted in patients with RRMM in China, demonstrating 
that treatment outcomes may be better if lenalidomide/dex-
amethasone is initiated early rather than after several pre-
vious therapies [18].
Furthermore, despite potential concerns of resistance in 
patients previously exposed to thalidomide, a subgroup analy-
sis of MM-009 and MM-010 showed that lenalidomide/dex-
amethasone was superior to placebo plus dexamethasone, 
regardless of prior thalidomide exposure [29]. In a recent 
“real world” study in 212 patients with RRMM, the quality 
of response to lenalidomide/dexamethasone was found to 
be independent of previous lines of therapy or prior exposure 
to either thalidomide or bortezomib [30].
In a separate subanalysis of MM-009 and MM-010, con-
tinuation of lenalidomide treatment until disease pro-
gression, after achievement of at least a partial response, 
was associated with a significant survival advantage (hazard 
ratio [HR], 0.137; 95% confidence interval [CI], 0.045–0.417; 
P=0.0005) when controlling for patient characteristics 
(number of prior MM therapies, 2-microglobulin levels, 
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and Durie-Salmon disease stage) [31]. Each additional lenali-
domide cycle was also associated with longer survival (HR, 
0.921; 95% CI, 0.886–0.957; P＜0.0001) [31]. Furthermore, 
continuing treatment with lenalidomide/dexamethasone to 
achieve best response, in the absence of disease progression 
and toxicity, provided deeper remissions and greater clinical 
benefit over time [32].
A number of recent studies have demonstrated the feasi-
bility of long-term treatment with lenalidomide/dex-
amethasone in patients with RRMM [33, 34]. A retrospective 
analysis from a single-center German study in 67 non-se-
lected patients with RRMM compared Kaplan-Meier survival 
estimates between the total population, patients receiving 
lenalidomide for ＞12 months, and patients discontinuing 
therapy after ＜12 months [33]. The median OS times in 
the total patient population, in patients treated for ＞12 
months, and in those who stopped lenalidomide after ＜12 
months for reasons other than disease progression, were 33.2, 
42.9, and 20.2 months, respectively (P=0.027) [33]. Thus, 
the analysis showed that the OS of patients receiving lenali-
domide for ＞12 months was superior when compared with 
that of patients who discontinued lenalidomide after ＜12 
months for reasons other than disease progression. These 
data confirm the potential use of lenalidomide as a continuous 
long-term treatment strategy [33].
In a study conducted by the French Intergroupe Franco-
phone du Myélome (IFM), 50 patients with RRMM received 
lenalidomide/dexamethasone for ≥2 years (median duration 
3 years [range, 2–7 years]) [34]. Response rates of at least 
partial response and very good partial response were achieved 
in 96% and 74% of patients in the overall cohort, respectively. 
At 37 months’ follow-up, the percentages of patients free 
from progression were 78.3% and 91.3% (odds ratio [OR] 
11.052 [95% CI: 0.94–129.91]; P=0.025) for patients exposed 
to lenalidomide for 2 to ＜3 years and ≥3 years, respectively. 
There were no notable changes in the incidence of adverse 
events in patients who received lenalidomide/dex-
amethasone for ＞3 years [34].
￭ Expert recommendations
• Based on the approved indication, lenalidomide (in com-
bination with dexamethasone) is recommended for the treat-
ment of MM in patients who have received at least 1 prior 
therapy. However, the expert panel highlights that lenalido-
mide is currently reimbursed in Korea only for patients after 
bortezomib treatment failure.
• Optimally, based on clinical evidence, lenalidomide 
should be administered as early as possible after first relapse 
and continued until disease progression.
DOSE AND SCHEDULE
Based on data from the 2 pivotal phase III trials, MM-009 
and MM-010, the standard recommended dosing schedule 
for oral lenalidomide is 25 mg/day on days 1–21 of each 
28-day cycle [10]. The starting dose of lenalidomide requires 
adjustment according to renal function or cytopenia (see 
‘Renal insufficiency’ and ‘Cytopenia’), but lenalidomide dose 
adjustment is not required on the basis of patient age or 
disease stage.
For patients with aggressive disease, the recommended 
starting dose of dexamethasone is 40 mg/day on days 1–4, 
9–12, and 17–20 of each 28-day cycle for the first 4 cycles, 
then 40 mg/day for 1–4 days. An alternative, slightly lower, 
dexamethasone dosing schedule is 40 mg/day on days 1–4 
and 15–20 of each 28-day cycle for the first 4 cycles, then 
40 mg/day for 1–4 days. The dexamethasone dose can be 
reduced according to patient age (see ‘Elderly patients’).
However, as discussed in more detail later, it is important 
to note that, in a retrospective analysis of Korean patients 
with RRMM who received lenalidomide/dexamethasone, it 
was found that the majority of physicians favored the use 
of a low-dose dexamethasone schedule (160 mg per cycle): 
oral dexamethasone 40 mg/day on days 1, 8, 15, and 22 
of each 28-day cycle [17]. According to our survey regarding 
the dose and schedule of dexamethasone, the regimen of 
40 mg/day once a week for 4 weeks was the most preferred 
schedule.
Patients with normal renal function and complete blood 
counts (CBCs) at baseline may be monitored every 2 weeks 
for the first 2–3 cycles of lenalidomide/dexamethasone. 
Patients with neutropenia, thrombocytopenia, or renal im-
pairment may require more intensive monitoring. For pa-
tients who have experienced no complications after 2–3 cy-
cles, monitoring every 4 weeks should be sufficient [21].
Elderly patients
MM is commonly observed in elderly individuals [35]. 
Based on the 2011 cohort of Korean patients, the median 
age at MM diagnosis is 67 years [36] and the increasing 
age of the overall Korean population is postulated to be 
among the reasons for the rise in the incidence of MM 
in recent years [5].
In a pooled, retrospective subanalysis of MM-009 and 
MM-010, lenalidomide/dexamethasone improved the ORR 
and led to prolonged PFS, TTP, and OS compared with place-
bo plus dexamethasone, irrespective of the age of patients 
[37]. Three age-specific subgroups were defined: patients 
aged ＜65 years (N=390), patients aged 65–74 years (N=232), 
and those aged ≥75 years (N=82). The ORR with lenalido-
mide/dexamethasone was similar in all 3 groups and con-
sistently higher than that achieved with dexamethasone 
alone (P＜0.0001 for all age groups). In each age group, 
the median PFS and the median TTP were also consistently 
higher with lenalidomide/dexamethasone than with dex-
amethasone alone (P＜0.001 for all age groups), indicating 
that the benefit of lenalidomide/dexamethasone over dex-
amethasone alone is independent of patient age. Increasing 
age, however, was associated with an increased incidence 
of anemia, febrile neutropenia, deep vein thrombosis (DVT), 
neuropathy, and gastrointestinal disorders. Although dose 
modification was more common in patients aged ≥75 years, 
there was no indication that dose reduction limited the bene-
fits of lenalidomide therapy [37]. Overall, these findings 
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from the age-specific subanalysis were consistent with those 
from the overall MM-009 and MM-010 study populations. 
Indeed, international guidelines state that lenalidomide/dex-
amethasone is an appropriate treatment option for patients 
with RRMM, regardless of age [21].
In current daily clinical practice, a reduced dose of lenali-
domide is often used for RRMM. According to a recent 
study from the Greek Myeloma Study Group, the initial 
dose of lenalidomide was higher in patients aged ＜65 years 
compared with that in older patients; the recommended 
starting dose of lenalidomide (25 mg) was administered in 
84.5% of patients aged ＜65 years compared with 64.5% 
of older patients (P=0.02) [30].
￭ Expert recommendations
• In the absence of other factors (e.g., renal impairment, 
cytopenia), lenalidomide can be administered, without dose 
reduction, regardless of age.
Dexamethasone: dose and schedule
Standard, high-dose dexamethasone should be considered 
in certain cases, such as for patients with spinal cord com-
pression, hypercalcemia, pain, or renal failure [21, 35].
The use of a lower total dose of dexamethasone (compared 
with standard, high-dose dexamethasone) has been asso-
ciated with a reduced incidence of serious adverse events 
(including thromboembolic complications) and early deaths, 
particularly within the first 4 months of therapy, when ad-
ministered to patients with newly diagnosed MM [38].
As noted earlier, although starting doses of lenalidomide 
and dexamethasone in the retrospective analysis of 110 pa-
tients with RRMM in Korea were based on MFDS recom-
mendations, the majority of patients started on lenalidomide 
25 mg on days 1–21 (84.5%) and dexamethasone 160 mg 
per cycle (61.8%) [17]. The lower dexamethasone dose and 
schedule (40 mg/day on days 1, 8, 15, and 22 of a 28-day 
cycle) were based on data from the US Eastern Cooperative 
Oncology Group (ECOG) E4A03 trial conducted in 445 pa-
tients with newly diagnosed MM [38]. In this study, lenalido-
mide/low-dose dexamethasone was associated with sig-
nificantly better short-term OS (96% [95% CI, 94–99] vs. 
87% [95% CI, 82–92], P=0.0002, at 1 year) and lower toxicity 
(grade 3 or worse: 35% vs. 52% of patients, P=0.0001) than 
lenalidomide/high-dose dexamethasone [38].
In the MM-009 and MM-010 studies, the dexamethasone 
dose was modified (due to toxic effects), at the investigator’s 
discretion, to 1 of the following levels: 40 mg/day for 4 
days every 2 weeks (dose level, -1), 40 mg/day for 4 days 
every 4 weeks (dose level, -2), or 20 mg/day for 4 days 
every 4 weeks (dose level, -3) [15, 16].
Although few prospective, well-controlled studies have 
analyzed the effects of low-dose dexamethasone in combina-
tion with lenalidomide in the RRMM setting, the use of 
low-dose dexamethasone with lenalidomide is recommended 
because it offers improved tolerability with no loss of efficacy 
compared with the standard regimen [21]. In addition, the 
following age-related dexamethasone modifications have 
been recommended by an international consensus panel [21]: 
age ＜65 years: 40 mg/day on days 1–4 and 15–18 of each 
28-day cycle for the first 4 cycles, then 40 mg/day weekly 
(days 1, 8, 15, 22 of each 28-day cycle); age 65-75 years: 
40 mg/day weekly; age ＞75 years: 20 mg/day weekly.
￭ Expert recommendations
• In combination with lenalidomide, a low-dose dex-
amethasone schedule is recommended due to improved toler-
ability compared with standard high-dose dexamethasone.
• High-dose dexamethasone may be considered in certain 
cases, such as for patients with spinal cord compression, 
hypercalcemia, pain, or renal failure.
• Age-adjusted dexamethasone dose reductions are re-
commended.
Renal insufficiency
Lenalidomide undergoes minimal metabolism in humans 
and is eliminated predominantly via urinary excretion in 
an unchanged form [39]. Consequently, lenalidomide dosing 
must be adjusted based on creatinine clearance (ClCr; assessed 
using the Cockcroft-Gault or MDRD [Modification of Diet 
in Renal Disease] equations) (Fig. 1).
In a pooled retrospective analysis of the MM-009 and 
MM-010 trials, lenalidomide/dexamethasone treatment was 
effective in patients with RRMM, irrespective of the degree 
of baseline renal impairment [40]. There were no significant 
differences in clinical response between patients with mild 
or no renal impairment (ORR 64%) and patients with moder-
ate (ORR 56%) or severe (ORR 50%) renal impairment. 
However, at a median follow-up of 31.3 months, median 
OS was significantly longer in patients with mild or no 
renal impairment than in patients with moderate or severe 
renal impairment (38.9 months vs. 29.0 months and 18.4 
months, respectively; both P=0.006). Importantly, 70% and 
86% of patients with moderate (ClCr ≤30 to ＜60 mL/min; 
N=80) or severe (ClCr ＜30 mL/min; N=14) renal impairment, 
respectively, experienced improved renal function during 
treatment with lenalidomide/dexamethasone. It is also nota-
ble, however, that significantly more patients (P＜0.05) with 
moderate (40%) or severe (38%) renal impairment than with 
mild/no renal impairment (22%) required a dose reduction 
or interruption because of an adverse event [40].
Overall, these data indicate that, with appropriate mod-
ification of lenalidomide dosing according to renal function 
(Fig. 1), lenalidomide/dexamethasone can be administered 
to RRMM patients with renal impairment (who may not 
have other treatment options) without excessive toxicity [41]. 
Furthermore, it has been shown that lenalidomide/dex-
amethasone may improve renal function in a substantial pro-
portion of RRMM patients with renal impairment [41, 42].
Recent data from European clinical studies have reinforced 
the fact that lenalidomide-based treatment is highly effective 
and represents an attractive treatment option in patients 
with MM with impaired renal function [43, 44]. In a retro-
spective, multicenter analysis of 26 patients with RRMM 
and impaired renal function (ClCr ＜60 mL/min), the ORR 
(at least a partial response) was 84% and the rate of renal 
response (at least a minor renal response) was 42% (6 patients 
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Fig. 1. International consensus recommendations for identifying the optimal lenalidomide starting dose (when used in combination with 
dexamethasone) in patients with relapsed or refractory multiple myeloma, according to baseline renal function and cytopenia [21]. Each 
lenalidomide cycle is 21 days out of 28 days. Reproduced with permission from Macmillan Publishers Ltd: Leukemia, copyright 2011.
achieved a complete renal response) [43]. Lenalidomide/dex-
amethasone has also shown efficacy with acceptable toxicity 
in 20 elderly patients (median [range] age 76.5 [68–85] years) 
with relapsed (N=7) or refractory (N=13) MM and moderate 
to severe renal failure (ClCr ＜50 mL/min) [44]. In both 
studies, the lenalidomide dose was adjusted according to 
the degree of renal impairment.
￭ Expert recommendations
• With appropriate dose modification, lenalidomide can 
be administered to patients with varying degrees of renal 
impairment.
• In patients demonstrating improved renal function, le-
nalidomide dosing can be increased with caution.
Cytopenia
Lenalidomide can cause significant neutropenia and 
thrombocytopenia. Preventive measures are often required 
in patients at high risk of developing neutropenia and throm-
bocytopenia, and supportive treatment (see ‘Hematologic 
toxicities’) is necessary in patients who develop cytopenia 
during therapy [45]. Lenalidomide should be used with cau-
tion in patients with baseline thrombocytopenia (platelet 
count ＜50,000/L or ＜30,000/L in patients with heavy 
marrow infiltration with myeloma) or neutropenia (absolute 
neutrophil count [ANC] ＜1,000/L) [23]. While there is 
insufficient evidence for a standard approach for the manage-
ment of cytopenia, current international expert opinion in-
dicates that lenalidomide can be initiated, with caution, in 
patients with cytopenia, provided that frequent monitoring 
of CBCs and appropriate management strategies, including 
growth factor support (granulocyte-colony stimulating factor 
[G-CSF] for neutropenia) and/or platelet transfusions, and 
lenalidomide dose modification, are implemented [10, 21, 
23, 24]. If changes in the CBC occur, the lenalidomide dose 
should be adjusted by 1 dose step in each cycle (e.g., from 
25 mg/day to 15 mg/day per cycle) (Fig. 1) [21].
￭ Expert recommendations
• If frequent monitoring of CBCs and appropriate manage-
ment strategies are implemented, including growth factor 
support (G-CSF for neutropenia) and/or platelet transfusions 
and lenalidomide dose interruption/reduction, lenalidomide 
can be initiated, with caution, in patients with cytopenia.
• Patients with existing cytopenia require more frequent 
monitoring.
PROPHYLACTIC MANAGEMENT OF ADVERSE EVENTS
Venous thromboembolism
Data from the 2 pivotal phase III multinational registration 
studies (MM-009 and MM-010) indicated that the incidence 
of VTE with lenalidomide/dexamethasone treatment in pa-
tients with RRMM was 8.8%–14.7% [15, 16].
The risk of VTE is associated with the type of regimen 
used: lenalidomide/high-dose dexamethasone (18%) ＞ lena-
lidomide/low-dose dexamethasone (4%)≈dexamethasone 
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Table 3. Prophylactic management of venous thromboembolism (VTE).
Risk level Management
Recent VTE within 6 months or immobilization or 
lenalidomide/high-dose dexamethasonea)
LMWH (enoxaparin 40 mg or dalteparin 5,000 IU daily), or warfarin (INR 2-3) if ClCr ＜30 
mL/min or platelets ＜50,000/L
Duration: first 4 cycles then switch to aspirin 100 mg daily
Other riskb) of VTE and platelets ≥100,000/L Aspirin 100 mg daily with cautious monitoring of bleeding for the duration of 
lenalidomide/dexamethasone
No VTE risk or platelets <100,000/L No prophylaxis with close monitoring of VTE-related symptoms
a)Dexamethasone 480 mg/month. b)Elderly patients aged ≥75 years, history of VTE, ECOG PS 2 or more, medical comorbidity such as infection, 
renal disease, pulmonary disease, congestive heart failure, arterial thromboembolism, hereditary or acquired thrombophilia, concomitant 
erythropoietin therapy, body mass index ≥30 kg/m2 [56, 64].
Abbreviations: ClCr, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; INR, International Normalized 
Ratio; LMWH, low molecular-weight heparin.
(3.4%–4.7%)≈lenalidomide (＜4%) [46].
Without prophylaxis, the incidence of VTE associated with 
lenalidomide/dexamethasone was similar in patients with 
newly diagnosed MM and RRMM (0.8% and 0.7%, re-
spectively) based on a systematic review and meta-analysis 
[47]. Similarly, the rates of VTE in patients undergoing 
thromboprophylaxis with aspirin were 0.9% (95% CI, 0.5–
1.5) and 0.6% (95% CI, 0.01–2.1), respectively [47]. The 
incidence of VTE is highest in the first few months after 
initiation of lenalidomide/dexamethasone, followed by a re-
duced incidence [48].
Based on Korean Health Insurance Review and Assessment 
Service (HIRA) data, the incidence of VTE in Korea in general 
is approximately one-tenth of that in Western populations 
[49]. However, the risk of advanced cancer-associated VTE 
in Korea has been shown to be similar to that in Western 
populations [50-53].
Compared with data from the MM-009 and MM-010 stud-
ies, a retrospective analysis of data from 110 Korean patients 
with RRMM who received lenalidomide/dexamethasone 
showed a relatively low incidence of VTE (2.7%) [17]. Similar 
findings have been reported previously in Asian patients 
with RRMM receiving thalidomide [54, 55]. However, as 
part of a preventative management strategy, all patients to 
be treated with lenalidomide/dexamethasone therapy for 
RRMM should be assessed for their additional risk of VTE, 
with platelet counts checked prior to the start of therapy 
and the appropriate method of thromboprophylaxis consid-
ered (Table 3) [23, 56].
￭ Expert recommendations
• When the combination of lenalidomide and dex-
amethasone is considered for patients with RRMM, it is 
important to assess each patient’s VTE risk and consider 
appropriate prophylaxis (Table 3).
• Four months’ injection of low-molecular weight heparin 
(LMWH) or administration of warfarin are appropriate pro-
phylactic measures for patients with additional VTE risk 
factors such as recent VTE, immobilization, or lenalidomide 
combined with high-dose dexamethasone (480 mg/month).
• Patients without additional VTE risk factors or those 
with platelet counts ＜100,000/L should be monitored for 
VTE symptoms without prophylaxis.
Infection and teratogenicity
Despite the frequent occurrence of neutropenia in RRMM 
patients treated with lenalidomide/dexamethasone, the regi-
men is generally not associated with febrile infectious epi-
sodes [45]. In MM-009/MM-010 and MM-016 (expanded 
safety experience), grade 3 or higher pneumonia occurred 
in 9.1% and 7.1% of patients with RRMM treated with 
lenalidomide/dexamethasone [26, 57]. Pneumonia (grade 3 
or higher) was also found to occur in 9.1% of patients in 
a retrospective Korean study in which 110 patients with 
RRMM received lenalidomide/dexamethasone [17].
An analog of thalidomide, lenalidomide has demonstrated 
teratogenic effects in monkeys [58]. The potential transfer 
of lenalidomide from a male undergoing treatment with 
lenalidomide to a female partner via semen during un-
protected intercourse is a concern. Human pharmacokinetic 
data indicate that lenalidomide is detected in human semen, 
but only at a very low percentage of the administered dose 
(＜0.01%) [39, 59]. Consequently, caution should be ex-
ercised in women of childbearing potential and in sexually 
active male patients. Complete abstinence or contraception 
must be used by female patients of childbearing potential, 
and male patients must practice complete abstinence or use 
condoms throughout the treatment duration, including dose 
interruptions, and for 1 week after treatment discontinuation 
if their partner is pregnant or is of childbearing potential 
and does not use contraception [10].
￭ Expert recommendations
• To prevent infection, routine antibiotic prophylaxis 
(e.g., trimethoprim-sulfamethoxazole, quinolones, or pen-
icillin) is highly recommended for the first 3 cycles of lenali-
domide when combined with dexamethasone, particularly 
for patients with aggressive disease or a history of neutropenia 
or infectious complications [21].
• The use of vaccinations, including influenza, should 
also be considered in MM patients.
• Due to the teratogenic potential of lenalidomide, caution 
must be exercised in women of childbearing potential and 
in sexually active male patients.
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TREATMENT OF ADVERSE EVENTS
Neutropenia, thromboembolic events, thrombocytopenia, 
anemia, and pneumonia were the most commonly reported 
grade 3 or higher adverse events in the MM-009 and MM-010 
trials after long-term follow-up [26]. The most common grade 
3 or higher adverse events reported in the expanded safety 
study (MM-016) were hematologic events (45%), fatigue 
(10%), and pneumonia (7%) [57]. The toxicity profile of 
lenalidomide/dexamethasone in patients with RRMM in 
Asian studies has generally been shown to be comparable 
to that reported in multinational studies [17-19]. Of note, 
unlike thalidomide and bortezomib, lenalidomide-based 
therapy is rarely associated with peripheral neuropathy. 
During long-term follow-up of patients in the MM-009 and 
MM-010 studies, the incidence of grade 2 and 3 peripheral 
neuropathy was only 1.4% [26]. No grade 3 or 4 peripheral 
neuropathy has been reported in studies conducted in Asian 
patients [17, 18].
Hematologic toxicities
The most common grade ≥3 hematologic toxicities, occur-
ring significantly more often with lenalidomide/dex-
amethasone than with dexamethasone/placebo in the 
MM-009 and MM-010 studies, were neutropenia (35.5% vs. 
3.4%; P＜0.05), thrombocytopenia (13.0% vs. 6.3%; P
＜0.05), and anemia (10.8% vs. 6.0%; P＜0.001) [26]. 
Hematologic toxicities (45%) also represented the most com-
mon grade ≥3 adverse events in the lenalidomide expanded 
access program in patients with RRMM [57]. In a Korean 
study, neutropenia (59.1%), anemia (43.7%), and thrombocy-
topenia (43.6%) were the most common grade 3-4 hemato-
logic adverse events reported in 110 patients with RRMM 
who received lenalidomide/dexamethasone [17].
Neutropenia and thrombocytopenia are clinically sig-
nificant and usually occur during the initial lenalido-
mide/dexamethasone cycles, with a decreasing frequency 
thereafter [48]. They are generally predictable and manage-
able [60].
￭ Expert recommendations
• At the beginning of each new cycle, lenalidomide treat-
ment should be delayed for 1 week if neutropenia (ANC 
＜1,000 cells/L) is present. When severe neutropenia (ANC 
500 cells/L) occurs, lenalidomide treatment should be inter-
rupted and G-CSF support should be added. If not contra-
indicated, dexamethasone should be continued.
• Lenalidomide treatment can be resumed if ANC has 
returned to 1,000 cells/L [23, 26, 45]. If ANC remains 
＜1,000 cells/L, a lenalidomide dose reduction, by 1 dose 
step, is necessary [45]. Further episodes of grade 3 or higher 
neutropenia require lenalidomide interruption (until ANC 
rises to ＞1,000 cells/L) and/or dose reductions [45].
• Management of low platelet counts (＜30,000 cells/L) 
involves a combination of platelet transfusions, lenalidomide 
dose modification, or treatment discontinuation [23, 26].
Non-hematologic toxicities
Pulmonary thromboembolism and deep vein thrombosis
A retrospective subgroup analysis of data from 353 patients 
with RRMM treated with lenalidomide/high-dose dex-
amethasone in the 2 pivotal studies, MM-009 and MM-010, 
assessed whether the subsequent development of VTE had 
an impact on survival. Overall, 17% of patients developed 
VTE, but they did not experience shorter OS or TTP [61].
Although the treatment of cancer-associated thrombosis 
remains challenging, and it is limited by the paucity of evi-
dence-based data, anticoagulation is the established corner-
stone of treatment. The decision as to whether to treat with 
an anticoagulant or not depends on an assessment of the 
severity of thrombus burden, risk of bleeding, convenience 
of treatment, potential interaction with anticancer therapy, 
and life expectancy [62]. Based on American College of Chest 
Physicians guidelines, LMWH is the preferred therapy for 
both initial and long-term anticoagulation treatment [63]. 
Alternative anticoagulation therapy may consist of un-
fractionated heparin, warfarin, or new oral anticoagulants 
(e.g., rivaroxaban or dabigatran). In patients with active can-
cer, anticoagulation can be extended beyond 3 months [63]. 
Table 4 outlines special considerations in cancer-associated 
VTE treatment [64].
￭ Expert recommendations
• Anticoagulation is the standard treatment when patients 
develop pulmonary thromboembolism (PTE) and/or DVT 
during lenalidomide/dexamethasone treatment.
• Severity of thrombus burden, risk of bleeding, con-
venience of treatment, interaction with anti-cancer treat-
ment, and life expectancy should be considered before the 
start of anticoagulation. LMWH is recommended preferen-
tially over warfarin or new oral anticoagulants in the treat-
ment of PTE/DVT.
Secondary primary malignancies
A post hoc analysis of pooled data from the MM-009 
and MM-010 trials reported a low incidence of secondary 
primary malignancies (SPMs) in patients with RRMM who 
received lenalidomide/dexamethasone [65]. Overall, in lena-
lidomide/dexamethasone recipients, there were 2 cases of 
myelodysplastic syndromes (MDS), 8 cases of solid tumors, 
and no cases of AML or B-cell malignancies. Standardized 
incidence ratios indicated that patients with RRMM treated 
with lenalidomide/dexamethasone had no increased risk of 
developing solid tumors [65]. Another analysis which as-
sessed pooled data from 11 lenalidomide-containing studies 
in 3,839 patients with RRMM, including some with a lenali-
domide treatment duration ≥2 years, demonstrated an SPM 
incidence rate of 2.15 per 100 patient-years, including MDS 
(8 cases), B-cell malignancies (2 cases), and AML (1 case). 
However, the incidence of SPMs was considered consistent 
with the incidence observed previously [66].
￭ Expert recommendations
• Appropriate caution should be exercised to ensure that 
patients treated with lenalidomide are followed up closely 
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Table 4. Special conditions in cancer-associated venous thromboembolism (VTE) [64].
Condition Management
Superficial vein thrombosis Catheter removal if catheter-related;
Anticoagulation therapy for 6 weeks if the thrombus is both non catheter-related and close to the 
deep vein system, especially the common femoral vein
Isolated calf vein thrombosis Watch and follow-up 2 weeks later if patient has no severe symptoms;
Anticoagulation therapy if patient has severe symptoms and no contraindication to anticoagulation
Extensive DVT (ileofemoral DVT) or 
massive PTE (systolic BP <90 mmHg)
Catheter-directed or intravenous thrombolysis if patient has no bleeding riska)
Central venous catheter-related 
thrombosis
Anticoagulation for 3 months;
Catheter removal only in cases with an infected or dysfunctional catheter
Retrievable IVC filter Only considered if patient is during the period of absolute contraindication to anticoagulationb)
a)History of hemorrhagic stroke or stroke of unknown origin; intracranial tumor; ischemic stroke within 3 months; history of major trauma, 
surgery or head injury within 3 weeks; platelets ＜100,000/L; active bleeding; bleeding diathesis. b)Recent CNS bleed; intracranial or spinal 
lesion at high risk for bleeding; active bleeding with more than 2 units transfused in 24 hours.
Abbreviations: BP, blood pressure; CNS, central nervous system; DVT, deep vein thrombosis; IVC, inferior vena cava; PTE, pulmonary 
thromboembolism.
with regard to monitoring/assessment of SPM.
Other adverse events
Based on data from the expanded safety experience with 
lenalidomide/dexamethasone in patients with RRMM 
(MM-016), other commonly reported non-hematologic ad-
verse events (all grades) included fatigue (55.4%), con-
stipation (23.7%), muscle cramps (23.5%), diarrhea (20.7%), 
nausea (18.9%), and rash (12.9%) [57]. Corresponding data 
from a retrospective analysis of 110 Korean RRMM patients 
treated with lenalidomide/dexamethasone indicated slightly 
lower incidence rates of these adverse events: fatigue (45.5%), 
constipation (17.2%), muscle cramps (10.9%), diarrhea 
(10.8%), nausea (7.2%), and rash (10.0%) [17]. Anorexia was 
reported at a higher incidence in the Korean study than 
in the MM-016 expanded safety study (20.9% vs. 10.2%) 
[17, 57]; the clinical relevance, if any, is unclear. Although 
not reported in any of the clinical trials of lenalidomide/dex-
amethasone in patients with RRMM, cases of potential lenali-
domide-associated hepatotoxicity [67] and thyroid dysfunc-
tion [68] have been recorded in the literature.
￭ Expert recommendations
• In general, symptoms such as fatigue, diarrhea, con-
stipation, and rash can be managed routinely without the 
need for lenalidomide dose adjustment.
• In specific cases, at the discretion of the treating physi-
cian, severe adverse events may warrant lenalidomide dose 
reduction, interruption, or discontinuation until the event 
has resolved.
• Routine liver and thyroid function monitoring is recom-
mended during lenalidomide therapy.
CONCLUSION
Evidence from pivotal multinational clinical trials has 
demonstrated the superior efficacy and predictable and man-
ageable tolerability profile of lenalidomide when used in 
combination with dexamethasone, compared with dex-
amethasone alone, in patients with RRMM [15, 16]. Recent 
additional evidence from clinical trials conducted in Asian 
patients with RRMM [17-19], real world experience [30, 
69], and a systematic review and meta-analysis of randomized 
controlled clinical studies of lenalidomide-based treatment 
for patients with MM [70], provides further support for the 
use of lenalidomide/dexamethasone in patients with RRMM.
Based on a recent epidemiologic analysis of 3,405 Asian 
patients with MM, there do not appear to be any significant 
ethnic differences between Western and Asian populations 
with regard to clinical or cytogenetic features of MM [17]. 
Nevertheless, given the rapidly increasing incidence of MM 
in Korea [17], similar to increases being observed in other 
Asian countries [71], there are requirements for a set of 
practical guidelines that will assist Korean clinicians to man-
age their patients better.
Recent Asian resource-stratified guidelines for the man-
agement of MM recognize that, at a pan-Asian level, the 
delivery of optimal care to all patients with MM is hindered 
due to large economic and healthcare infrastructure dis-
parities, and varying access to novel drugs [72]. At a coun-
try-specific level, even in Asian countries which fall into 
the high-income category, with national healthcare systems, 
restrictions on healthcare reimbursement are often imposed 
which can limit the availability and/or use of specific drugs 
[72]. In Korea, lenalidomide has been reimbursed since 
March 2013 for patients with RRMM who have failed borte-
zomib treatment.
With regard to ongoing and potential future developments, 
lenalidomide is being evaluated in various therapeutic combi-
nations in patients with RRMM. It is also being evaluated 
as maintenance therapy following autologous stem cell trans-
plantation (SCT). Other investigational combinations cur-
rently being evaluated in early phase clinical trials include 
lenalidomide in combination with everolimus, and lenalido-
mide/dexamethasone in combination with panobinostat, 
bevacizumab, SGN-40, perifosine, vorinostat, dasatinib, 
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NPI-0002, or carfilzomib [73]. Lenalidomide is also being 
evaluated as monotherapy in patients who have relapsed 
after prior SCT [73]. Although these investigational studies 
will have no short-term impact on the current indicated 
use of lenalidomide in Korean patients with RRMM, data 
from ongoing clinical studies are awaited with anticipation.
Furthermore, given the continual focus by stakeholders 
on the use of healthcare resources, an alternative lenalido-
mide dosing (on alternate days) schedule has recently been 
evaluated in a preliminary retrospective UK analysis of 39 
patients with RRMM experiencing grade 3 or 4 hematologic 
toxicity [74]. The alternative schedule yielded significant 
cost savings, while maintaining efficacy, compared with the 
recommended lenalidomide dose reduction. Prospective 
evaluation of the alternative dosing schedule is warranted.
In summary, lenalidomide is a distinct second-generation 
immunomodulatory drug that possesses activity against hem-
atologic malignancies, in particular MM. The combination 
of lenalidomide/dexamethasone is approved for the treat-
ment of patients with RRMM. Results from multinational 
pivotal phase III trials in this setting have demonstrated 
that lenalidomide/dexamethasone leads to significantly im-
proved OS compared with dexamethasone alone. In addition, 
smaller studies in Asian populations (including Korea) sup-
port the findings from pivotal trials, demonstrating that lena-
lidomide is an effective option in the treatment of RRMM 
in Korea. Optimal clinical benefits are seen when lenalido-
mide/dexamethasone is initiated at first relapse and con-
tinued, beyond best treatment response, until disease 
progression. Importantly, lenalidomide has a predictable and 
manageable tolerability profile, with minimal neurotoxicity, 
allowing long-term administration. Future studies will de-
termine the efficacy and safety of lenalidomide in novel 
combinations, with potentially complimentary agents, for 
the treatment of RRMM.
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